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TransplantatABSTRACT
Introduction. Malignant diseases are well-known complications after lung transplantation
(LT). Among these, inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with a
not well-known and often aggressive biological behavior.
Material and Methods. We hereby describe 2 cases of cystic fibrosis patients who
underwent bilateral sequential LT (BSLT) complicated by IMT.
Results. A 26-year-old man presented a right endobronchial lesion 6 months after BSLT.
Two consecutive fiber bronchoscopic biopsies showed granulation tissue. For the persistent
lesion growth, the patient underwent a transthoracic biopsy showing histologic diagnosis of
IMT. Therefore, he underwent to right pneumonectomy that was unfortunately
complicated after 6 months with a late bronchopleural fistula and empyema with exitus
6 months later. A 31-year-old woman 1 year after BSLT presented with a left
voluminous pleural-parenchymal lesion; the histologic examination after biopsy revealed
an IMT. She underwent a removal of the lesion with a macroscopic R0 resection.
Histologic, immunophenotypic, and cytogenetic examinations showed a strong
overexpression of anaplastic lymphoma kinase requiring biological adjuvant therapies;
however, the patient refused it. Four years later, she presented a recurrence treated with
debulking procedure and adjuvant radiotherapy. At last follow-up, the patient was alive
with stable disease and optimal graft function.
Conclusions. Although IMT is a rare complication after lung transplant, to obtain a
careful diagnosis, an early and aggressive treatment is mandatory.*Address correspondence to Dr Camilla Poggi, Division of
Advanced Thoracic Surgery and Lung Transplant, Sapienza
University of Rome, AOU Policlinico Umberto I, Viale del Poli-
clinico 155, 00161, Rome, Italy. Tel/Fax: þ390649970220.
E-mail: camilla.poggi@uniroma1.itL UNG transplantation (LT) is the only viable thera-peutic option for selected patients affected by end-
stage pulmonary diseases. Although several improvements
have occurred in surgical techniques, perioperative man-
agement, and immunosuppressive regimens with increased
quality of life and long-term survival, the outcome is still
influenced by the development of complications occurring
in the different post-transplant periods [1]; in particular, the
LT recipients show an higher risk to develop malignanciesAuthors. Published by Elsevier Inc. This is an open
le under the CC BY-NC-ND license (http://
mons.org/licenses/by-nc-nd/4.0/).
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ion Proceedings, XX, 1e4 (2019)related to continuous administration of immunosuppressive
drugs to prevent rejection [2e4]. Although lymphoprolifer-
ative disorders and skin cancers are the most frequent0041-1345/19
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2 POGGI, PECORARO, CARILLO ET ALneoplasms, other solid cancers may occur [5]. Inflammatory
myofibroblastic tumor (IMT) is a rare mesenchymal
neoplasm showing an indolent biological and clinical
behavior, although sometimes a more aggressive behavior
and recurrences have been described. The respiratory and
the gastrointestinal tracts are the most frequent localiza-
tions showing site-specific symptoms, but a general inflam-
matory syndrome with fever and malaise may often be
present [6]. Although surgical resection is the gold standard
treatment, adjuvant therapy regimens have recently been
proposed. Because approximately one half of IMTs show a
translocation activating the anaplastic lymphoma kinase
(alk) receptor leading to an overexpression of alk protein,
biological therapies with inhibitors of kinase domain have
been administered, showing good results [7]. We hereby
describe 2 cases of cystic fibrosis patients undergoing bilat-
eral sequential LT (BSLT) who developed IMT.Fig 1. Inflammatory myofibroblastic tumor. Areas of spindle
cells (blue arrow) with plump nuclei and minimal cytological aty-
pia admixed with chronic inflammatory infiltrate (black arrow)
composed of lymphocytes and plasma cells. (Hematoxylin-eosin,
magnification 20x).CASE #1
At the 6-month follow-up after BSLT, a 26-year-old cystic
fibrosis patient presented with a cough, exertional dyspnea,
and severe restrictive pattern at the pulmonary function test.
A chest computed tomography scan showed a hilar mass
extensively invading the right main bronchus. A fiber optic
bronchoscopy showed a friable and bloody tissue almost
completely occluding the right main bronchus; a histologic
examination on multiple biopsies described granulation tis-
sue. In order to obtain airway patency, he underwent me-
chanical dilation and vaporization with a neodymium-yttrium
aluminum garnet laser and prosthesis placement (DUMON
12 x 30 mm; Novatech SA, La Ciotat, France) in the right
main bronchus. Because of the impressive and fast growth of
the mass, the patient underwent a transthoracic biopsy with
the histologic diagnosis of IMT. Histologically, we observed a
proliferation composed of spindle cells characterized by
eosinophilic, elongated, tapering cytoplasmic processes
without striation and oval nuclei with smooth contours, open
chromatin, and occasional nucleoli. These cells were
admixed with an intense chronic inflammatory infiltrate
composed of lymphocytes, plasma cells, and macrophages.
The neoplastic spindle cells were immunoreactive for
vimentin, smooth muscle actin and EMA and negative for
cd34, calretinin, human bone marrow endothelial cell
marker-1, s100 and desmin, thus showing a myofibroblastic
differentiation (Fig 1). The involvement of the hilum and the
fissure plan required a right pneumonectomy. The post-
operative course was uneventful. After 6 months, the patient
presented with a cough and fever, and a bronchopleural fis-
tula associated to pleural empyema was detected. The pa-
tient underwent rigid bronchoscopy and airway stenting with
a conical and fully coated self-expanding metallic stent, with
a proximal diameter (tracheal) of 22 mm, a distal diameter
(bronchial) of 16 mm, and a length of 50 mm (TRACHE-
OBRONXANE SILMET; Novatech SA,). A chest tube was
positioned; through it, pleural lavages with antiseptic solu-
tion were daily performed. Because of a Candida albicansand Pseudomonas aeruginosa infection, therapy with intra-
venous (IV) colistin (loading dose followed by maintenance
therapy: 6-9 million IU 4.5 twice daily) was immediately
established in combination with nebulized colistin (1 million
IU every 8 hours) and caspofungin (50 mg daily IV). After an
initial improvement of clinical conditions, the empyema
persisted, requiring an open window thoracostomy. Never-
theless, the patients died of a multiorgan failure caused by
sepsis 3 months later.CASE #2
One year after BSLT, a 31-year-old cystic fibrosis female
reported with a hacking cough. A chest computed tomog-
raphy scan showed a left voluminous pleural-pulmonary
mass, and the histologic examination after biopsy revealed
an IMT, a myofibroblatic proliferation of spindle cells with
small size nuclei, and scanty cytoplasm mixed with abundant
inflammatory lymphoplasmocellular infiltrate and amor-
phous eosinophilic extracellular matrix. At the immunohis-
tochemistry examination, the neoplastic cells were positive
for smooth muscle actin, vimentin and alk and negative for
cd34, bcl2, cd99, desmin, and s100. She underwent a
removal of the lesion with a macroscopic R0 resection. The
postoperative course was uneventful, and the patient was
discharged 7 days after surgery. The rearrangements of the
ALK gene was confirmed by FISH, and this data required
biological adjuvant therapies; however, the patient refused
it. Four years later, she experienced an IMT recurrence; she
underwent a redo surgery, but this time the surgical
INFLAMMATORY MYOFIBROBLASTIC TUMOR AFTER TRANSPLANT 3resection was R1. Postoperative prolonged air leaks were
treated with multiple autologous blood patches. The patient
was discharged 20 days after surgery, and she underwent
adjuvant radiotherapy on the surgical field with a total of
50.4 Gy in 28 fractions of 1.8 Gy each (IMRT and Tomo-
Therapy HI ART, Madison, Wisc). At her 1-year follow-up,
the patient was alive with stable disease and optimal graft
function.DISCUSSION
Malignant diseases are well-known complications after LT
[2]. Transplant recipients show an increased risk compared
to the general population to develop malignancies, and
approximately 16% and 32% of them experience cancer
within 5 and 10 years after the transplant, respectively [8].
The immunosuppressive regimen plays a crucial role as
shown by several studies, although the pathogenesis of lung
cancer in this specific subset of patients is not completely
known [9]. IMT has been reported with a number of syno-
nyms: plasma cell granuloma, inflammatory pseudotumor,
xanthogranuloma, and fibrous histiocytoma. IMT represent
less than 1% of all lung tumors and rarely can involve the
airway; its biological behavior is not well known [10,11].
This tumor is the most frequently diagnosed pediatric lung
neoplasm, and its precise cause is unknown, although it
seems to be related to an uncontrolled response to tissue
damage of chronic inflammation normally after pulmonary
infections or in patients who had an history of cancer [12].
The diagnosis is not simple, and different histologic classi-
fications have been proposed. The World Health Organi-
zation defined it as lesion composed of a myofibroblastic
spindle cell population accompanied by an inflammatory
infiltrate of plasma cells, lymphocytes, and eosinophils
[13,14].
Approximately 50% of IMTs contain ALK gene rear-
rangements [7]. ALK gene rearrangements or the resulting
fusion proteins may be detected in tumor specimens using
immunohistochemistry, and thus fluorescence in situ hy-
bridization should be used to confirm the results. Although
the true neoplastic nature of the lesion has not been
established yet, the evidence of chromosomal rearrange-
ment involving the ALK gene that results in the activation of
a tyrosine kinase receptor has been supposed to be involved
in the pathogenic process [15]. In patients with alk-positive
IMT that otherwise show only 10% response with tradi-
tional chemotherapy, new biological therapies using
inhibitors of the kinase domain of alk protein have shown an
impressive response rate. There is no clear correlation
between the alk expression and the clinical behavior of the
tumor, although the high rate of response in alk inhibitors
seems to correlate the alk positivity to a good prognosis [15].
To the best of our knowledge, these are the first 2 cases of
IMT after LT. In literature, only few cases of IMT after
solid organ transplant have been reported. Tepeoglu et al
reported a case of a 9-month-old child who underwent liver
transplant for biliary atresia (the donor was his mother).Two months after transplant, the authors detected
post-transplant lymphoproliferative disorder and IMT
concurrently, advocating this entity to highlight possible
Epstein-Barr virus involvement [16]. IMT is an uncommon
secondary malignancy after hematopoietic stem cell trans-
plant, too. Shash et al reported the case of highly aggressive
and metastatic IMT in an 8-year-old girl following an
umbilical cord blood transplant [17]. Furthermore, the
interaction of an immunosuppressive regimen and
infections has been supposed in a case of IMT secondary to
invasive pulmonary aspergillosis in a patient with chronic
graft-versus-host disease [18]. IMT of the lung usually shows
locally invasive behavior with high rate of recurrence that
has been reported to range from 18% to 40% and meta-
static potential. Complete surgical resection, when feasible,
is the gold standard [10,19]. After R0 resection, an excellent
prognosis has been reported. Fabre et al reported [10] a
10-year survival rate of 89% and Cerfolio et al (12) a 5- and
10-year survival of 91% and 77%, respectively, although a
60% recurrence rate in patients undergoing R1 resection
has been described. After surgery in cases of incomplete
resection or metastatic spread or as the primary treatment
when surgery is not feasible, radiotherapy and conventional
chemotherapy seem to be useful [20].
After major lung resection and LT, postoperative com-
plications can occur both in the first postoperative period
and for a long time following the operation. Among these
infections, postoperative air leaks and bronchopleural fis-
tula are extremely common. Early detection and fast treat-
ment are crucial for a positive outcome because these
conditions are often associated with high rates of morbidity
and mortality [21]. Pulmonary infections due to viral, bac-
terial, or even fungal pathogens are common complications
after lung transplant due to an immunosuppressive regimen;
robust therapy is needed to avoid hematic dissemination
and sepsis. In MDR-GN infections, colistin is widely used
administered by inhalation and IV with good results [22].
Postoperative air leaks contribute to prolonged hospitali-
zation and can delay adjuvant chemotherapy or radio-
therapy. Many techniques have been proposed for the
treatment of this complication, and autologous blood
patches have shown good results [23]. Postpneumonectomy
bronchopleural fistula associated with empyema still
remains a dreaded complication in thoracic surgery. The
positioning of a conical fully coated SEMS together with a
toilette of the infected pleural space usually allow a com-
plete resolution, as we previously reported [24,25]. Unfor-
tunately, the immunosuppressive regimen in these patients
played a negative role, and in the first case, this procedure
was not able to clear the infection and suddenly led to the
patient’s death.
In conclusion, although IMT is a rare complication after
LT, an early diagnosis is mandatory to correctly treat and
obtain good results. When feasible, complete surgical
resection is the gold standard. Chemotherapy and radio-
therapy, especially after incomplete resection, could be
useful to prevent disease progression.
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